<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Valsartan - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../sickbay-shared.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Valsartan</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Cardiac / Vascular</div>
      <h1>Valsartan</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Valsartan 40mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Hypertension (continuation therapy onboard)</strong>
            <ul>
              <li>Typical maintenance dose: 80–160 mg PO once daily</li>
              <li>Onboard stock is 40 mg tablets: if patient normally takes 80 mg, give 2 x 40 mg tablets once daily</li>
              <li>Do NOT initiate new hypertension therapy onboard without medical direction; valsartan is for continuation of established regimens</li>
            </ul>
          </li>
          <li><strong>Heart failure (continuation therapy onboard)</strong>
            <ul>
              <li>Target dose typically 160 mg twice daily (if already established)</li>
              <li>Onboard 40 mg tablets allow for dose adjustments; follow patient's established regimen from home</li>
            </ul>
          </li>
          <li><strong>Post-myocardial infarction (continuation therapy)</strong>
            <ul>
              <li>Typical dose: 20–160 mg twice daily (based on established regimen)</li>
              <li>Ensure patient has been taking this medication prior to boarding; do not initiate new therapy</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Continuation of established hypertension treatment (patient ran out or lost medication)</li>
          <li>Continuation of heart failure treatment (when patient on ARB therapy)</li>
          <li>Continuation of post-MI therapy in patients who cannot tolerate ACE inhibitors</li>
          <li>NOTE: Valsartan should NOT be newly initiated onboard—only used to continue established therapy</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to valsartan or ARBs</li>
          <li>Pregnancy: AVOID—risk of fetal toxicity and death (renal dysgenesis, oligohydramnios, IUGR). If pregnancy detected, discontinue immediately</li>
          <li>Bilateral renal artery stenosis or single kidney with renal artery stenosis (risk of acute renal failure)</li>
          <li>Hyperkalemia or high risk of hyperkalemia (concurrent K-sparing diuretics, CKD, diabetes)</li>
          <li>Severe hepatic impairment or biliary obstruction</li>
          <li>Volume depletion/dehydration: risk of hypotension; ensure adequate hydration before dosing</li>
          <li>Do NOT combine with ACE inhibitors or direct renin inhibitors (aliskiren)—increased risk of hypotension, hyperkalemia, renal dysfunction</li>
          <li>NSAIDs: reduce antihypertensive effect and increase renal dysfunction risk; use caution</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Hypotension, dizziness, orthostatic hypotension</li>
          <li>Hyperkalemia (monitor K+ levels if feasible, especially in renal impairment or diabetes)</li>
          <li>Acute renal failure or worsening renal function (especially in volume depletion, renal artery stenosis, or concurrent nephrotoxic drugs)</li>
          <li>Headache, fatigue</li>
          <li>Angioedema (rare but serious; less common than with ACE inhibitors)</li>
          <li>Cough (much less common than ACE inhibitors)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>PO tablet; may take with or without food</li>
          <li>Ensure patient is well-hydrated before administering (avoid in dehydration or acute volume loss)</li>
          <li>Confirm patient's usual dose before dispensing; match home regimen as closely as possible with 40 mg tablets</li>
          <li>If patient normally takes 80 mg once daily, give 2 x 40 mg tablets once daily</li>
          <li>Monitor BP if feasible; adjust dose only with medical direction</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Blood pressure (sitting and standing); watch for hypotension/orthostasis</li>
          <li>Renal function (if labs available): monitor creatinine and BUN, especially in older adults, CKD, or concurrent diuretics/NSAIDs</li>
          <li>Electrolytes (if labs available): monitor potassium for hyperkalemia</li>
          <li>Volume status: ensure adequate hydration; avoid in dehydration or acute illness with poor PO intake</li>
          <li>Signs of angioedema: facial/tongue swelling, difficulty breathing (rare; discontinue immediately and treat)</li>
          <li>Symptoms of hypotension: dizziness, lightheadedness, syncope</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>ONLY use valsartan for continuation therapy—do NOT initiate new treatment onboard without clear medical direction</li>
          <li>Confirm patient's home regimen and usual dose before dispensing; document clearly</li>
          <li>If patient is dehydrated (vomiting, diarrhea, heat illness), hold valsartan until volume status normalized—risk of hypotension and renal injury</li>
          <li>Avoid concurrent NSAIDs when possible (risk of renal dysfunction and reduced BP control); use acetaminophen for pain if appropriate</li>
          <li>Pregnancy screening: if female of childbearing age, confirm not pregnant before continuing ARB therapy</li>
          <li>If patient develops significant hypotension, dizziness, or orthostasis, hold dose and rehydrate; contact medical direction for guidance</li>
          <li>If labs unavailable and patient has diabetes or known CKD, use caution and monitor clinically for hyperkalemia signs (weakness, arrhythmia)</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (valsartan tablets): <a href="https://pdf.hres.ca/dpd_pm/00066746.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00066746.PDF</a></li>
          <li>Health Canada product monograph (Diovan – valsartan reference): <a href="https://pdf.hres.ca/dpd_pm/00022982.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00022982.PDF</a></li>
          <li>Medscape reference (valsartan): <a href="https://reference.medscape.com/drug/diovan-valsartan-342332" target="_blank" rel="noopener">https://reference.medscape.com/drug/diovan-valsartan-342332</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
